Anti-IL-17/TNFR fusion protein IPR: anti-IL-17 antibody/TNFR ECD fusion protein and its uses (Patent Application No.: 201711137039.8, PCT/CN2018/114079),IL-17 and TNF-α have significant synergistic effects in cell signalling pathways and in promoting inflammatory mediators. Therefore, it is of great prospect to develop IL-17 and TNF-α bispecific antibodies for autoimmune diseases. Anti-IL-17 and TNFR fusion proteins, there are no immunogenicity problem, would be the world's first anti-IL-17 and TNF-α bispecific antibodies with better efficacy than Taltz if developed successfully.

Gene recombinant monoclonal antibody series of medical injection products, mainly used in the treatment of: firstly, a variety of tumours (e.g. metastatic breast cancer, prostate cancer, giant cell bone tumours); secondly, osteoporosis; thirdly, rheumatoid arthritis and other symptoms.